Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer

被引:0
|
作者
Hao Chen [1 ]
Dan-Ping Shen [1 ]
Zi-Zhen Zhang [1 ]
Jia-Hua Liu [1 ]
Yan-Ying Shen [2 ]
Xing-Zhi Ni [1 ]
机构
[1] Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
[2] Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
关键词
Gastric cancer; Fibroblast growth factor receptor 4; Protein expression; Clinicopathological characteristics; Prognosis;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
100214 ;
摘要
AIM:To investigate fibroblast growth factor receptor4(FGFR4)protein expression in Chinese patients with resectable gastric cancer(GC)and the association with clinicopathological characteristics and survival.who underwent curative surgical procedures were enrolled in this study.The protein expression of FGFR4 in formalin-fixed,paraffin-embedded(FFPE)GC tissues was determined by immunohistochemical(IHC)analysis.Patient clinicopathological data and survival information were also collected andχ2 statistical analysis was performed to analyze FGFR4 protein expression in the subgroups with differing clinicopathological characteristics including;gender,age,tumor location,differentiation,tumor-node-metastasis stage,macroscopic type,depth of invasion,lymph node metastases,distant metastasis,neural invasion and vascular invasion.Furthermore,some common molecular markers of GC in our cancer center,including p53,p27,topoisomeraseⅡα(TopoⅡα)were also determined by IHC and their association with FGFR4 protein expression evaluated.The probability of survival for different subgroups with different clinicopathological characteristics was calculated using the Kaplan-Meier method and survival curves plotted using the log rank test.RESULTS:Seventy seven cases(44%)were found to have high expression of FGFR4 protein.Significantly different FGFR4 expression was observed between gastric cancers with differing expression of TopoⅡα(log rankχ2=9.4760,P=0.0236).No significant differences were observed between subgroups defined by any of the other clinicopathological characteristics.The median survival time of the FGFR4 high expression(77 cases)and low expression groups(98 cases)was27 mo and 39 mo,respectively.The five-year survival rates and median survival times of gastric cancers with high FGFR4 expression were worse than those with low expression(30.8%vs 39.2%,27 mo vs 39 mo),respectively,however,no significant difference was observed in survival time(log rankχ2=1.0477,P=0.3060).Survival analysis revealed that high expression of FGFR4 was a predictor of poor outcome in GC patients if the tumor was small(less than or equal to 3cm in size)(log rankχ2=5.5033,P=0.0190),well dif-ferentiated(log rankχ2=7.9757,P=0.0047),and of T1 or T2 stage invasion depth(log rankχ2=4.8827,P=0.0271).CONCLUSION:Our results suggest that high tumor expression of FGFR4 protein is not an independent risk factor for GC cancer initiation,but is a useful prognostic marker for GC patients when the tumor is relatively small,well differentiated,or in the early stages of invasion.
引用
收藏
页码:1838 / 1844
页数:7
相关论文
共 50 条
  • [21] Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer
    Elakad, Omar
    Lois, Anna-Maria
    Schmitz, Katja
    Yao, Sha
    Hugo, Sara
    Lukat, Laura
    Hinterthaner, Marc
    Danner, Bernhard C.
    Von Hammerstein-Equord, Alexander
    Reuter-Jessen, Kirsten
    Schildhaus, Hans-Ulrich
    Stroebel, Philipp
    Bohnenberger, Hanibal
    CANCER MEDICINE, 2020, 9 (10): : 3574 - 3583
  • [22] Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features
    Durcan, Emre
    Keskin, Fatma Ela
    Ozkaya, Hande Mefkure
    Sirolu, Sabri
    Sahin, Serdar
    Korkmaz, Ozge Polat
    Gazioglu, Nurperi
    Tanriover, Necmettin
    Comunoglu, Nil
    Oz, Buge
    Kizilkilic, Osman
    Kadioglu, Pinar
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2022, 130 (02) : 125 - 133
  • [23] Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas
    La Rosa, S
    Sessa, F
    Colombo, L
    Tibiletti, MG
    Furlan, D
    Capella, C
    JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (01) : 37 - 41
  • [24] Epidermal growth factor receptor (EGFR): Mutational and protein expression analysis in gastric cancer
    Mammano, Enzo
    Belluco, Claudio
    Sciro, Manuela
    Mencarelli, Roberto
    Agostini, Marco
    Michelotto, Mauro
    Marchet, Alberto
    Nitti, Donato
    ANTICANCER RESEARCH, 2006, 26 (5A) : 3547 - 3550
  • [25] Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer
    Han, Biao
    Liu, Jian
    Ma, Min-Jie
    Zhao, Lin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (14) : 2188 - 2192
  • [27] Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
    Hierro, C.
    Alsina, M.
    Sanchez, M.
    Serra, V.
    Rodon, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2017, 28 (06) : 1207 - 1216
  • [28] Expression of fibroblast growth factor 2 mRNA in early and advanced gastric cancer
    Noda, M
    Hattori, T
    Kimura, T
    Naitoh, H
    Kodama, T
    Kashima, K
    Pignatelli, M
    ACTA ONCOLOGICA, 1997, 36 (07) : 695 - 700
  • [29] Expression of Fibroblast Growth Factor Binding Protein in Head and Neck Cancer
    Li, Weimin
    Wang, Chuan
    Juhn, Steven K.
    Ondrey, Frank G.
    Lin, Jizhen
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2009, 135 (09) : 896 - 901
  • [30] Epidermal growth factor receptor superfamily: protein expression and gene amplification status in gastric cancer
    Marques, E. F.
    Begnami, M. D.
    Sabrina Kato Hashimoto, S. K.
    Neto, C. C.
    Soares, F. A.
    HISTOPATHOLOGY, 2010, 57 : 91 - 91